Company intelligence / Profile preview

Oncalis

Schlieren, Zurich, Switzerland

Ownership: Private
Development stage: Other

Overview

Oncalis AG was a Swiss biotechnology company founded in 2006 as a spin-off from ESBATech AG to focus on small molecule drug discovery. Headquartered in Schlieren, Switzerland, the company specialized in developing orally available kinase inhibitors for the treatment of various cancers. Its core technology was a yeast-cell based, high-throughput screening platform designed to identify potent inhibitors of receptor tyrosine kinases (RTKs). In 2008, Oncalis expanded its portfolio by in-licensing a family of PI3K inhibitors from ChemDiv, including the lead candidate ONC-201. However, the company was unable to progress its candidates into clinical trials and was eventually liquidated around 2012.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

ChemDiv

Beyond the preview

Go deeper on Oncalis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncalis.

Explore the full profile